Recent research into retatritide peptide highlight notable outlook for treating weight and type 2 diabetes. The peptide, a dual agonist of glucagon-like peptide-1 and GIP, seems to present improved weight loss and blood sugar control compared existing treatments. Ongoing clinical trials are requi